To evaluate time to rebound (i.e., increase in joint symptoms after therapy discontinuation) in patients with Psoriatic Arthritis (PsA) enrolled in the US Corrona Registry who achieved Low Disease Activity prior to stopping

Trial Profile

To evaluate time to rebound (i.e., increase in joint symptoms after therapy discontinuation) in patients with Psoriatic Arthritis (PsA) enrolled in the US Corrona Registry who achieved Low Disease Activity prior to stopping

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top